글로벌 고트리글리세리드혈증 시장 – 2029년까지의 산업 동향 및 예측

고중성지방혈증 시장 분석 및 규모

글로벌 시알로레아 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 약물 승인과 제품 출시는 글로벌 고트리글리세리드혈증 시장에서 활동하는 시장 참여자에게 많은 성장 기회를 창출할 것으로 예상됩니다. 이러한 트리글리세리드 수치 증가는 주로 콜레스테롤 수치가 높지 않더라도 심혈관 질환과 죽상경화증의 소인과 관련이 있습니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 고중성지방혈증 시장의 성장률을 분석합니다. 글로벌 고중성지방혈증 시장의 예상 CAGR은 언급된 예측 기간 동안 약 4.59%인 경향이 있습니다. 시장은 2021년에 10162.59백만 달러로 평가되었으며 2029년까지 14552.10백만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

고중성지방혈증 시장 범위 및 세분화

Market Definition

Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms of hypertriglyceridemia.

Global Hypertriglyceridemia Market Dynamics

Drivers

• Increased Consumption of Unhealthy Diet

Higher consumption of unhealthy food and lifestyle is projected to expand the scope of growth of the global hypertriglyceridemia market. Increased demand for hypertriglyceridemia medications for use in the point-of-care healthcare sector to provide a solution for the requirement of preventive methods, is in return is, increasing the demand for this market.

• Higher Drug Approvals

The growing number of drug approvals are anticipated to help companies build their market position. For instance, in December 2019, Amarin received FDA approval for VASCEPA (icosapent ethyl) which is indicated for reducing cardiovascular risk. The novel indication for VASCEPA is that it is an adjunct to diet to diminish triglyceride levels in aged patients with severe hypertriglyceridemia. This boosts the market growth.

Opportunities

• Growing Elderly Population

Life expectancy is increasing all over the globe, which has led to an upsurge in the aging population. This trend positively impacts the industry by increasing the disease occurrence and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) results in the sound growth of the global hypertriglyceridemia market during the forecast period. Thus, it creates more opportunities for the market growth.

• Increased R&D Activities

Major market players are investing to in development of novel drugs and launching these products in the market which in turn, is projected to significantly increase the market growth and create productive growth opportunities in the global hypertriglyceridemia market during the forecast period. For instance, in July 2019, Sun Pharma launched ‘Ezallor Sprinkle’ in the U.S. for people with difficulty swallowing. Ezallor Sprinkle capsules are indicated as an addition to the diet for the treatment of hypertriglyceridemia adult patient. It is also indicated for treating adult patients with type III hyperlipoproteinemi and other lipid-lowering treatments. These new treatment methods are creating more opportunities for the market.

 Restraints/Challenges

• Lack of Medical Care

The lack of medical care in undeveloped economies may restrain the growth of hypertriglyceridemia market during the forecast period. Not much awareness leads to the unavailability of treatment and limits market growth.

• High Cost

The huge expenditure associated with these therapeutics such as fibrates, niacin, omega-3 fatty acids hamper the market growth. The huge drug development and associated processes hamper the market's growth.

This global hypertriglyceridemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypertriglyceridemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Covid-19 Impact on Global Hypertriglyceridemia Market

The hypertriglyceridemia market growth has been impacted majorly because of COVID-19 worldwide. According to EMCrit project, COVID-19 affected patients are more susceptible to having hypertriglyceridemia, primarily because of systemic inflammation. Therefore, ideally keeping the propofol dosages can help to maintain sedation and prevent conditions such as hypertriglyceridemia. It is difficult for several researchers and major market players to perform clinical trials during this pandemic crisis. However, in the post-pandemic era, numerous market players such as Eli Lilly and Company, and Pfizer are investing in research and development of novel hypertriglyceridemia drugs.

Global Hypertriglyceridemia Market Scope

The global hypertriglyceridemia market is segmented on the basis of type, drugs, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary Hypertriglyceridemia
• Secondary Hypertriglyceridemia
• Others

Drugs

• Pharmacological
• Non-Pharmacological
• Emerging Treatments
• Others

Drug class

• Statins
• Atorvastatin
• Fluvastatin
• Fibrates
• Clofibrate
• Fenofibrate
• Niacin
• Nicotinic acid
• Nicotinamide
• Omega-3 Fatty Acids
• Alpha-linolenic acid (ALA)
• HMG-CoA Reductase inhibitors
• Altoprev
• Amlodipine/atorvastatin.
• Atorvastatin

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hypertriglyceridemia Market Regional Analysis/Insights

The global hypertriglyceridemia market is analysed and market size insights and trends are provided by type, drugs, drug class, distribution channel and end-user as referenced above.

The major countries covered in the global hypertriglyceridemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global hypertriglyceridemia market throughout the forecasted period due to advanced healthcare facilities and the presence of multiple treatment options.

North America dominates the market due to increased public–private partnerships to promote R&D activities for treatment of sialorrhea in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hypertriglyceridemia Market Share Analysis

글로벌 고트리글리세리드혈증 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 글로벌 고트리글리세리드혈증 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 고중성지방혈증 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 파이저 주식회사(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Fresenius Kabi AG(독일)
• 히크마제약(일본)
• 노바티스 AG(스위스)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 브리스톨 마이어스 스퀴브 회사(미국)
• GSK 주식회사(영국)
• Bayer AG(독일)
• Sun Pharmaceutical Industries Ltd(인도)
• Accord Healthcare(영국)
• 워크하르트(인도)

SKU-54392